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Local sclerotherapy with Polydocanol (Aethoxysklerol®) for 
the treatment of Epistaxis in Rendu-Osler-Weber or Hereditary 
Hemorrhagic Telangiectasia (HHT): 15 years of experience*
Summary
Hereditary Haemorrhagic Telangiectasia or Rendu-Osler-Weber syndrome is a rare autosomal dominant vascular disease cha-
racterized by mucocutaneous and gastrointestinal telangiectases and localized arteriovenous malformations in lung, brain 
and liver.
Epistaxis, due to rupture of telangiectases of the nasal mucosa, is the most frequent clinical manifestation, leading in many 
cases to severe impairment of the quality of life in the patients. 
Though several treatments have been used to reduce epistaxis, none have been completely effective, with the exception of 
polydocanol (Aethoxysklerol®) in submucosal or subpericondrial injections, which was first presented in 2000 with very good 
results.
After fifteen years using polydocanol in submucosal injections on 45 patients and with nearly 300 injections, we have ob-
served that in 95% of all cases, their nose bleeds improved with respect to frequency and quantity without any important 
side effects. There was just one case of septal perforation, another with increased septal perforation, and one patient who 
suffered from dizziness and blurred vision for a few minutes. In this paper the results obtained using this technique over a 
fifteen-year period will be presented and evaluated.
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Introduction
Hereditary Hemorrhagic Telangiectasia (HHT) or Rendu-Osler-
Weber is a multisystemic disease with an autosomal dominant 
inheritance pattern and increased penetrance with age (1-3). It 
was first described by Sutton in 1864, and described as a new 
disease different from hemophilia in 1896. Osler and Weber each 
published their first reports in 1901 and 1907 respectively. The 
term ‘Hereditary Hemorrhagic Telangiectasia’ (HHT) was given 
by Hanes in 1909. Prevalence is estimated to be approximately 
1:5000-8000 inhabitants, with a certain degree of variability de-
pending on geographical areas (3-5). Although there are at least 
5 genes which can cause HHT clinical symptoms by mutation, 
90% are related with mutations in Endoglin, on chromosome 9 
or ALK1/ACVRL1 encoded on chromosome 12, leading to HHT1 
and HHT2, respectively. Other mutations have been identified in 
Smad4 (2%), causing the Juvenile Polyposis and Hemorrhagic Te-
langiectasia syndrome (JP-HHT). Moreover, mutations in two loci 
of chromosomes 5 and 7 are responsible for HHT3 and HHT4, 
but these genes have not yet been identified (6,7). The mutations 
lead to vascular malformations in different locations, such as te-
langiectases in the nasal and gastric mucosa and arteriovenous 
malformations in liver, lungs and brain. 
Epistaxis or nose bleeding is the most frequent clinical manifesta-
tion in HHT, but with variable intensity, appearing in 93% of HHT 
patients, 90% before the age of 21. Epistaxis results from ruptures 
of telangiectases present in the nasal mucosa, leading when 
severe, to recurrent visits to emergency units, periods in hospital 
and transfusions, thereby, endangering the physical integrity of 
patients and reducing their quality of life. To prevent a subjective 
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perception of epistaxis, Bergler et al., (8) established a graded 
scale to classify nose bleeds, both in intensity and frequency. 
However, epistaxis is not the only clinical symptom of these pa-
tients. The disease is a perfectly established syndrome with clear 
clinical diagnostic criteria, known as the Curaçao criteria (9).
Treatments used in the natural history of this disease, have va-
ried greatly, from mere packing, to selective and supraselective 
embolizations, including chemical cauterizations, laser and ar-
gon. In 2000, the use of polydocanol in submucosal infiltrations 
for the management of epistaxis was published for the first time 
(10). This treatment has been used for the past 15 years in a total 
of 55 patients, among them 45 with HHT, the rest being affected 
by different ENT pathologies (11). The number of injections given 
was 245, and no serious complications were observed during 
those years. In this manuscript we intend to demonstrate the ef-
ficacy and safety of this treatment in a sufficiently large number 
of cases to allay any fear triggered by previous publications 
where alternative products were used (12-15).
Material and methods
From 1996 to 2010, a total of 45 patients diagnosed with Rendu-
Osler-Weber syndrome, based on the clinical Curaçao criteria, 
were treated in the ENT unit of Valladolid University Hospital, 
Spain. 
Technical description of the procedure
Prior anesthesia of the nasal area to be treated, with a tetra-??
caine plus adrenaline- cotton plug embedded in the nasal 
cavity for 10 minutes.
0.5% Polydocanol, also known as Lauromacrogol 400 (0.5% ??
Aethoxysklerol®) (Kreussler Pharma, Ferrer Farma S.A, Spain) 
was used.
1 - 2 ml of Aethoxysklerol® infiltration in the septum or in the ??
telangiectasia area, in the submucosal and/or subpericondrial 
region with a 25 gauge needle (Spinocan). We only performed 
infiltrations in one nasal cavity, never bilaterally at the same 
time.
Hemostasis in the treated area was carried out with tetracaine ??
+ adrenaline. Exceptionally, Espongostan (gelatine sponge) or 
Surgicel were used to stop the post-infiltration hemorrhage.
One month after the first infiltration, and depending on the ??
response to the treatment, infiltrations would continue either 
in the same nasal cavity or switch to the other. The injections 
would be continued on a monthly basis until the epistaxis was 
controlled (infrequent and less intense nose bleeds). After-
wards infiltrations would be ‘on demand,’ when patients were 
again suffering from epistaxis. 
Statistic analysis
The statistical analysis was done using the SPSS statistical pack-
age for social sciences, 15.0 version. The quantitative variables 
are shown as plus or minus averages and the qualitative as well 
as the standard deviation (SD) as frequency distributions. To 
compare the EUROQOL-5D results before and after treatment, 
the Wilcoxon test was applied. 
Results
A total of 45 patients with ages ranging from 12-84 years (aver-
age 59.98 ± 14.5) were included in the study. Among them, 26 
were males (57.8%) with a mean age of 57.31 ± 14.4 years and 
19 females (42.2%) with a mean age of 63.63 ± 14.5. In our popu-
lation, 75.5% started to suffer from epistaxis before they were 20 
years old and the remaining 24.5% after this age. 
The frequency and intensity of epistaxis (Bergler et al., (8), Table 1) 
in all our patients corresponded with grades 2 and 3 for frequen-
cy and grades II and III for intensity, with the 3/III combination 
being the most common (Table 2). 
Table 3 gives a breakdown of the different treatments previ-
ously received by the patients, showing that most patients 
were treated with nose packages, chemical cauterization, 
and selective embolizations. As can be seen from Table 3, the 
combinations of these treatments vary, since patients have been 
treated by multiple and different therapeutic procedures. In the 
column marked ‘Others,’ we have included two patients who 
had previously been unsuccessfully treated with Ethybloc®, and 
one patient treated with Ethoxysclerol® 6 years ago, with good 
results but requiring new infiltrations, due to epistaxis. We have 
not included pharmacological treatments with antifibrinolytics 
or topical oestrogens in the table. 
Among the patients, 51.1%, had been given blood transfusions, 
but these have not been recorded as we do not consider them 
relevant to this study. 
The number of Aethoxysklerol® infiltrations is shown in Table 
4, where it can be seen that 51.1% of the patients received be-
tween 1 and 4 injections, while the remaining 48.9% received 5 
or more. The average number of infiltrations per patient is from 
5 to 6 in each nasal cavity. However, over the past 15 years some 
patients have received up to 16 or 18 injections, if both nostrils 
are taken into account (Table 4).
From Table 5 ‘Complications’, it is evident that the vast majority of 
patients, as many as 42, (93.3%) did not suffer any side effects after 
the injections. One patient suffered a septal perforation, and in an-
other patient, with a previous septal perforation, it became slightly 
enlarged. Finally, one other patient felt dizzy and had blurred 
vision for a few minutes after the injection, but these symptoms 
disappeared soon after, without any sequelae (Table 5).
Regarding treatment efficacy, the bleeding decreased in 
frequency and amount to a grade combination of 1/I in most 
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patients (73.2%), which means less than one bleeding per week, 
or in other words just a few blood spots on a handkerchief. A 
good response was observed in 21.9% of the patients where the 
bleeding decreased to grade 1-2/I-II, meaning that the patients 
might experience either the occasional haemorrhage soaking 
of a handkerchief, or just light bleeding more than once a week 
with only discrete stains on a handkerchief. Though there was 
no response in 2 patients (4.9%) and the response could not be 
recorded in 4 patients (8.9%), none of them worsened (Table 6). 
Discarding the 4 uncontrolled patients, the level of satisfaction 
was measured in the remaining patients by a questionnaire and 
the percentage calculated based on the remaining participants. 
Of the patients, 75.6% were very satisfied, 19.5% were quite 
satisfied, and 4.9% reported no change in satisfaction. None felt 
any worse (Table 6).  
The quality of life test, Euroquol-5D, was also applied, revealing 
a significant improvement in daily activity as well as consider-
able relief from pain and discomfort, and especially depression 
and anxiety (Table 7).   
Discussion
The treatments used to stop or prevent epistaxis are diverse, 
each with different degrees of success (16-18). Patients are often 
the experts, knowing the best way to stop epistaxis, based 
unfortunately on their current situation. For this reason, it is im-
portant to let them help us when they are admitted to hospital, 
because they are fully aware of their condition, and neglecting 
a patient’s advice may lead us into a difficult and frightful 
situation. Sometimes, they tell us of types of food that trigger 
epistaxis, and we suspect that this is due in some measure to the 
salicylate content of certain foodstuffs. For this reason, prescri-
bing anticoagulants or platelet antiaggregants (recommended 
for other people from a certain age on) should be carefully 
considered, evaluating risks against benefits (16). 
Topical treatments with humidifiers, Vaseline, and oestrogen-
containing ointments are also used by HHT patients with 
different results. Nose packing material has evolved in recent 
years, changing from gauze placed under pressure in the nostril 
to the introduction of neumopacking, sometimes embedded in 
procoagulant ointments to avoid bleeding after removal, such 
as Rapid-Rhino®. 
Pharmacological therapy has made use of aminocaproic and 
tranexamic acids (18), oestrogens and oestrogen receptor modu-
lators (tamoxifen and raloxifene), antiangiogenic drugs (Beva-
zicumab, Thalidomide, Interferon alpha or beta), immunosup-
pressors and iron supplements, some of them with promising 
results, others acting as coadjuvants.
 
Chemical cauterizations are not very efficient, and the electric 
scalpel systematically gives rise to septal perforations. However, 
laser in association with topical oestrogens is undoubtedly ef-
ficient (19), but as with the electric scalpel, may occasionally lead 
to septal perforations (20) and the treatment must be performed 
in a surgical environment under general anaesthesia.
More aggressive surgical techniques, such as septodermoplasty 
(21), Young’s occlusion (22) to avoid the aggression of air passing 
through the nose, the selective/supraselective embolizations or 
arterial ligations are reserved for patients that do not respond 
Table 1. Grading of frequency and intensity of nasal bleeding (8).
Frequency of Bleeding Intensity of Bleeding
Grade 1 Less than once per week Grade I Slight stain on handkerchief
Grade 2     Several times per week Grade II    Soaked handkerchief
Grade 3 More than once per day Grade III Bowl or similar utensil necessary
Table 2. Distribution of patients according to the Bergler/Sadick scale of epistaxis.
Frequency Intensity Combination of degrees
Degree Nº % Nº % 2/II 10 22.2 %
1/I 0 0 2/III 5 11.1 %
2/II 15 33.3 14 31.1 3/II 4 8.9 %
3/III 30 66.7 31 68.9 3/III 26 57.8 %
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to other techniques. Among them, the most efficient are the 
embolizations, although they tend to recanalize in time. We 
have observed several cases, where the embolization instead of 
decreasing epistaxis, worsened it. In relation to dermoplasty, we 
should mention that its effect, in many cases, is similar to that of 
the occlusive technique, decreasing the nostril lumen or even 
closing it, which makes it difficult to apply packaging tech-
niques when haemorrhages occur behind the valve. 
Sclerotherapy, using different compounds has also been used 
to treat epistaxis in HHT (10-15). We have had no experience using 
Ethybloc®, since it was not available to us, but according to the 
publications we have reviewed (14,15), it must be administered with 
general anesthesia therefore repeating the treatment would be 
complicated with the added risk of the anesthesia. 
Fibrin glue (Tissucol®) has also been used (12,13) but serious hyper-
sensitive side effects associated with its administration (13) even 
hemiplexia (12) have been reported. We have used Tissucol® on two 
occasions in operations without positive results; moreover, it is 
difficult to handle. In view of the aforementioned problems and 
side effects, it does not seem to be a recommendable treatment. 
Polydocanol or Lauromacrogol 400, is an acrylic compound of 
600 MW, which has a selective effect on the venous endothe-
lium, leading to a secondary thrombosis without necrosis in the 
surrounding tissue providing this is healthy and well irrigated. 
The septal perforation in simultaneous bilateral infiltrations was 
an exceptional side effect, only observed in one case, and that 
could have been due to poor mucosa irrigation, which is quite 
frequent in the damaged nostrils of these patients. As it is a 
stable compound at room temperature and has low viscosity, its 
administration is very simple and efficient in intralumen, submu-
cosal or subpericondrial injections. It is commercially available 
as Aethoxysklerol® (Kreussel Pharma) and comes in boxes con-
taining five 2 ml vials. We use vials of 0,5 % that contain 10 ml 
ethanol and 10 mg of polydocanol. 2 and 3% are also available, 
increasing the amount of polydocanol to 40 and 60 mg respec-
tively in the same volume of ethanol (9). For HHT purposes, we 
have used 0.5% in accordance with previous reports on varicous 
vein treatments (9).
We have treated 45 patients with Aethoxysklerol®, giving 245 in-
filtrations with highly satisfactory results, as far as control of fre-
quency and intensity of epistaxis are concerned. This technique 
is recommended for HHT due to its relatively easy application 
(whenever possible without the interference of haemorrhages 
or nose packing) and only needs local anaesthesia. Moreover, 
in those patients where the technique cannot be applied with 
local anaesthesia, injections can be carried out under total an-
aesthesia, though we have not needed to employ this option so 
far. Some of the problems related to the technique include the 
presence of crusts interfering with visibility, previous perfora-
tions, or the inexistence of septal cartilage to hold the infiltra-
tion needle and, of course, the immediate bleeding following 
the initial application. Nonetheless, in spite of these problems, 
all the patients were treated with the exception of two with per-
Table 3. Previous treatments received.
NP CC EB L SR SE VL D Others
n % n % n % n % n % n % n % n % n %
45 100 43 95.5 9 20 8 17.8 2 4.4 15 33.3 2 4.4 5 11.1 3 6.6
NP (Nose Packages); CC (Chemical Cauterization); EB (Electric blade); L(Laser); SR (Submucous resection); SE (Selective Embolization); VL (Vascular 
Ligation); D (Dermoplasty);  Others.
Table 4. Treatment with Aethoxysklerol®.
No. of inflitrations No. of nostrils infiltrated No. of infiltrations according to the Bergler/
Sadick (average)
1-4 doses 51.1 % One Nostril 16 (35.6%) 2/II 6.2
2/III 6.2
≥ 5 48.9 % Both Nostrils 29 (64.4%) 3/II 4.75
3/III 5.12
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Table 6.  Efficiency and treatment satisfaction.  
Efficiency Satisfaction
Nº % % valid(*) Nº % % valid (*)
Worse
Equal 2 4.4 4.9 2 4.4 4.9
Good 9 20.0 21.9 8 17.8 19.5
Very Good 30 66.7 73.2 31 68.9 75.6
No Evaluated 4 8.9 4 8.9
Total 45 100 100 45 100 100
(*)  Non evaluated patients are not contabilized.
Table 5. Complications.
Frequency Percentage
No complications 42 93.33
Foramen postinfiltration 1 2.22
Enlargement of previous foramen 1 2.22
Dizziness and blurred vision 1 2.22
Not evaluated 4 8.9
Total 45 100.0
manent packages, which impeded application. These two cases 
have been placed under ‘Equal’ in Table 6. 
The results obtained are very satisfactory with up to a 95% 
improvement in effectively controlling epistaxis, as well as a high 
level of patient satisfaction. The two patients shown as ‘Equal’ 
are the patients whose treatment could not be applied either 
because of continuous hospitalization in one case, or due to con-
tinuous nose packages in the other. Four patients could not be 
localized (Table 6). All the treated patients were satisfied because 
the severity of their epístaxis was reduced to such an extent 
that there was an overall general improvement, specifically with 
regard to their anaemia and associated asthenia as well as the re-
duced need for transfusions and visits to the hospital. These pa-
rameters have not been statistically evaluated in this study. The 
quality of life questionnaire clearly indicates an improvement 
after Aethoxysklerol® treatment, especially concerning anxiety 
and pain in these patients. As far as mobility and personal care 
are concerned, both the ageing process and the global nature of 
the question must be taken into account (Table 7). 
We should clarify that this treatment is not a definite cure. 
Despite telangiectasia removal with this technique, the genetic 
impairment in these patients means that, these will reappear. 
However, follow-up treatments with Aethoxysklerol® are much 
easier than at the beginning of  treatment. As stated in the 
Material and Methods section, once the patients are controlled 
with Aethoxysklerol® infiltrations, the successive infiltrations are 
‘on demand’ depending on their symptoms. 
Regarding the side effects of the technique, we have only 
recorded one septal perforation, which can be explained by the 
fact that two simultaneous infiltrations were made on both sides 
of the nasal wall. In another case, we have shown an enlarge-
ment of the preexisting perforation resulting from previous 
treatments. We cannot explain the observation of a short period 
(3 - 4 minutes) of dizziness and blurred vision in a patient fol-
lowing the infiltration. We have not observed this effect in other 
patients, not even in this patient who was subjected to posterior 
infiltrations.  
The first patients to be treated were recruited from ENT external 
consultations. Afterwards, the main source of patients was 
through the Spanish HHT Association. The periodical patient 
meetings organized by the association are where patients can 
speak about their experiences and treatments. Sierrallana Hos-
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pital in Cantabria (Northern Spain), the reference hospital for the 
Spanish HHT unit, is coordinated by Dr R. Zarrabeitia and sup-
ported by Dr L.M Botella from the Biological Research Centre, 
Madrid (CIB), where genetic studies are carried out and informa-
tion about the disease compiled. From Sierrallana Hospital, the 
patients are sent to our ENT unit, for the sclerosing treatment. At 
this moment, our ENT consultation unit is considered the refer-
ence unit in Spain for this treatment. 
Most of the patients attending our outpatients’ unit, with just 
a few exceptions, are patients with a long clinical history of the 
disease who have been subjected to multiple treatments. All of 
them suffer from epistaxis and have been subjected to multi-
ple packings, transfusions and cauterizations, etc. Therefore, 
in our clinical exploration, we not only observed the typical 
telangiectases, but also the complications due to previous 
treatments such as mucosal atrophy, sinequiae, lack of septal 
cartilage and even perforations. All of these conditions compli-
cate the manipulation of the nostrils, prone to bleeding due to 
mucosal fragility
Conclusions
Sclerosing infiltrations with Aethoxysklerol® are efficient to 1. 
control epistaxis in HHT or Rendu-Osler-Weber syndrome. 
The administration of this technique is not too complex, 2. 
as it does not require a general anaesthesia under normal 
conditions. 
Side effects are minimal, since we have only registered one 3. 
case of septal perforation from among 300 infiltrations, and 
another of enlargement of a pre-existing perforation due to 
the technique. 
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Authorship contribution
DM: The main author involved in the evaluation of  the sclero-
sing treatment and in the editing, of the present manuscript. 
TM: Help in the sclerosing treatment and in the revision of the 
clinical cases. RZ: Coordinator responsible for sending Rendu-
Osler patients from the reference hospital of Sierrallana, Tor-
relavega (Spain) for local sclerotherapy. LMB: Help in sending 
patients from the CIB (Madrid) and in editing the English edition 
of the manuscript. AA: Responsible for the design and statistical 
treatment of data.
References
Fontalba A,  Fernandez-L A ,  Garc ia-1. 
Alegria, E, et al. Mutation study of Spanish 
patients with Hereditary Hemorrhagic 
Telangiectasia. BMC Med Genet. 2008; 9: 
75-86.
Fe r n a n d e z - L  A ,  S a n z - R o d r i g u e z  F, 2. 
Zarrabeitia R, et al. Blood outgrowth endo-
telial cells from Hereditary Haemorragic 
Telangiectasia patients reveal abnormali-
ties compatible with vascular lesions. 
Cardiovasc Res. 2005; 68: 235-248.
Pérez  del  Mol ino A ,  Zar rabei t ia  R , 3. 
Fernández A. Telangiectasia Hemorragica 
Hereditaria. Med Clin (Barc). 2005; 124: 
583-587.
Kjelsen AD, Vase P, Green A. Hereditary 4. 
Haemorrhagic Telangiectasia: a popula-
tion-based study of prevalence and mor-
tality in Danish patients. J Intern Med. 
1999; 245: 31-39.
Jessurun GA, Kamphuis DJ, Van der Zande 5. 
FH, Nossent JC. Cerebral arteriovenous 
malformations in the Netherlands Antilles. 
High prevalence of hereditary hemorrhagic 
telangiectasia-related single and multiple 
cerebral arteriovenous malformations. Clin 
Neurol Neurosurg. 1993; 95: 193-198.
Cole SG, Begbie ME, Wallace GM, Shovlin 6. 
CL. A new locus for hereditay haemorrhag-
ic telangiectasia (HHT3) maps to chromo-
some 5. J Med Genet. 2005; 42: 577-582.
Bayrak-Toydemir P, Mcdonald J, Akarsu N, et 7. 
al. Fourth locus for hereditary hemorrhagic 
telangiectasia maps to chromosome 7. Am 
J Med Genet. 2006; 140: 2155-2162.
Bergler W, Sadick H, Götte K, Riedel F, 8. 
Hörmann K. Topical estrogens combined 
with argon plasma coagulation in the 
management of epistaxis in hereditary 
hemorrhagic telangiectasia. Ann Otol 
Rhinol Laryngol. 2002; 111: 222-228.







Mobility 1.07 0.385 1.12 0.431 0.317
Personal care 1.07 0.267 1.08 0..400 1.000
Daily activities 1.52 0.700 1.20 0.577 0.011
Pain/Discomfort 2.15 0.662 1.26 0.526 0.001
Anxiety/Depression 2.19 0.736 1.26 0.447 0.001
(**)  Wilcoxon`s test
86
Local injection of Aethoxysklerol® in HHT Epistaxis
Shovlin CL, Guttmacher AE, Buscarini E, et 9. 
al. Diagnostic criteria for hereditary hemor-
rhagic telangiectasia (Rendu-Osler-Weber 
syndrome). Am J Med Genet. 2000; 91: 
66-67.
Ramirez B, Morais D, Condado MA, Marcos 10. 
M, Martin G, Poncela M. Una nueva sus-
tancia esclerosante en el tratamiento de la 
enfermedad de Rendu-osler-Weber. Acta 
Otorrinolaring Esp. 2000; 51: 36-39.
Morais D, Ramirez B, Santos J. El tratami-11. 
ento local esclerosante con Aethoxysklerol 
en la patología ORL: Enfermedad de 
Rendu-Osler, Granulomas, Angiomas. Acta 
Otorrinolaring Esp. 2002; 53: 658-661.
Martin H, Martin C. Les injections de cole 12. 
ded fibrine dans les epistaxis graves et la 
malade de Rendu-Osler. Ann Oto-Laring 
parís. 1984; 101: 561-563.
Jankowsk i R,  Beaudouin E,  Kanny G, 13. 
Wayoff M, Moneret-Vautrin DA. Accidents 
d`hypersensibilité a la thrombine, con-
sécutifs a l`emploi de colles biologiques. 
Ann Otol-Laryng. (Paris) 1992; 109: 95-99.
Borsik M, Herbreteau D, Deffrennes D, et al. 14. 
Le traitment des épistaxis de la maldie de 
Rendu-Osler par injection intramuqueuse 
d`Ethibloc. Ann Oto-Laryng (Paris). 1992; 
109: 273-276.
R o u x - V a i l l a r d  S ,  Pa s c o - Pa p o n  A , 15. 
Laccourreye L, Dubin J. Treatment of 
epistaxis in Rendu-Osler-Weber disease by 
in situ Ethibloc® injections. J Neuroradiol. 
2004; 31: 110-115.
Faughnan ME, Palda VA, Garcia-Tsao G, et 16. 
al. International Guidelines for the diag-
nosis and management of hereditary 
hemorrhagic telangiectasia. J Med Genet. 
doi:10.1136/jmg.2009.069013.
Zarrabeitia R, Albiñana V, Salcedo M, Señaris-17. 
Gonzalez B, Fernandez-Forcelledo, JL, Botella 
LM. A review on clinical management and 
pharmacological therapy on Hereditary 
Haemorrhagic Telangiectasia (HHT ). Curr 
Vasc Pharmacol. 2010; 8: 473-481.
Morales-Angulo C, Perez del Molino A, 18. 
Zarrabeitia R, Fernandez A, Sanz-Rodriguez 
F, Botella LM. Tratamiento de las epistaxis 
en la telangiectasia hemorrágica hereditar-
ia (enfermedad de Rendu-osler-Weber) con 
ácido tranexámico. Acta Otorrinolaringol 
Esp. 2007; 58: 129-132.
Sadick H, Naim R, Oulmi J, Hörmann K, 19. 
Bergler W. Plasma surgery and topical estri-
ol: effects on the nasal mucosa and long-
term results in patients with Osler´s dis-
ease. Otolaryngol Head Neck Surg. 2003; 
129: 233-238.
Tomassin J-M, Dessi P, Ferman C, Dauvin 20. 
J-B, Bailhache A. Surgery in the septal 
per foration, in Encyclopedie Medico-
Chirurgicale :  Otorhinolar yngological 
Surgery. E-46-135.
Saunders WH. Septal dermoplasty for 21. 
control of nose bleeds caused by heredi-
tary hemorrhagic telangiectasia or septal 
perforations. Trans Am Acad Ophtalmol 
Otolaryngol. 1960; 64: 500-506.
Lund VJ, Howard DJ. Closure of the nasal 22. 
cavities in the treatment of refractory 
hereditary hemorrhagic telangiectasia. J 
laryngol Otol. 1997; 109: 95-99.
Dario Morais Pérez
Plaza Juan de Austria, 3-3º D
47006 Valladodid
Spain
E-mail: dmoraisp@gmail.com
Tel: +34-616259036
Fax: +34-983420091
